Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists a Phase 2 open-label extension study of elamipretide as terminated. The study was designed to assess long-term safety and tolerability in patients with genetically confirmed primary mitochondrial disease who previously participated in SPIMM-202.
- 01The registry lists the study status as TERMINATED.
- 02The extension focused on long-term safety and tolerability of elamipretide.
- 03The excerpt provides no reason for termination or study results.
Why it matters Editorial
The termination status is relevant to elamipretide’s clinical development, but the excerpt does not establish any safety or efficacy conclusions.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide